AgomAb Therapeutics
ActiveSummary
AgomAb Therapeutics has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €244.1m and a net result of -€9.6m. Equity has been growing by about 109% per year since 2018. Its solvency ranks better than 95% of 892 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 13-04-2017 Normal situation
- Registered office
- 10 active companies are registered at this address Source: KBO register, as of 2 November 2026.
- Activity
- Other technical testing and analysis NACE 71209and 2 others
- Joint committee
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2022
- Establishment unit
- 2.268.629.862 2600 Antwerpen, since 13-04-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 05-03-2026
Board and ownership
- Auditor
- BV PwC Bedrijfsrevisoren
Shareholders
- Advent France Biotechnologyact of 09-04-2019
- DE HAARD ANTIBODY TECHNOLOGIES B.V.act of 09-04-2019
- EUREMAB SRLact of 09-04-2019
- Holdings
- Shares in 2 companies Agomab Spain SLU and Agomab US Inc.
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts 2025
- Loss
- €9.6m
- ▼ 17.9%
- Equity
- €244.1m
- ▼ 3.8%
- Total assets
- €251.3m
- ▼ 2.8%
- Employees on 31-12-2025
- 53
- ▲ 1.9%
Filed on 23-06-2026, 38 days before the deadline
Score breakdownraises riskLoss of €9.6m, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 39.79, cash €73.0mSector: Architectural and engineering activities; technical testing and analysis (NACE 71)Equity €244.1m (97.1% of total assets)Show the evidence
Checked score
Score 2025
95
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 57% of medium-sized companies in architecture and engineering (NACE 71)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 97.1% of total assets
Liquidity
86+24
short-term debt 2.3% · cash 29.0%
Profitability
14+1
return on assets -3.8%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: 0.1%▲ +0.1 percentage points vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.2%▲ +0.1 percentage points vs 08-2026highest value
10-2026: < 0.1%▼ -0.2 percentage points vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Credit of up to €23,150,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 39.79 (58.17 in 2024), above the usual 1.5. Short-term debt is 2.3% and cash 29% of total assets. 2.9% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 71, medium-sized). It does better than 94% of them on solvency, 96% on liquidity, 11% on profitability and 27% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€9.6m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-06-2026, 38 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
38 days early
2024
58 days early
2023
34 days early
2022
28 days early
2021
32 days early
2020
68 days early
2019
74 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 47 days before the deadline. In the sector (NACE 71), the median for financial year 2024 was 8 days before the deadline, and 34% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Risk: 8 loss-making years in a rowloss in financial year 2025 -€9.6m View
- Caution: Lower net result than 95% of companies in architecture and engineeringsector median €35,976 · 894 companies -€9.6m View
- Board changedlatest change 11-09-2026 · 9 in office 2 joined · 1 left View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- Flemish supportawarded from 2022 to 2025 €4.3m View
- Positive: More staff in 2025from 40.9 FTE to 52 FTE ▲ 27.1% View
Recent changes
- · Gazette deed Capital increase of €229,347.31 to €303,287,161.22
- · Gazette deed Appointments: Marino Garcia (non-executive director) and Naimish Patel (non-executive director)
- · Gazette deed Reappointments: Ohad Hammer (director) and Tim Knotnerus (director)
Companies linked to AgomAb Therapeutics
Comparable companies
These companies have the same main activity as AgomAb Therapeutics: other technical testing and analysis (NACE 71209). They are comparable in size and age: total assets between €47m and €97m, founded between 1994 and 2011.
| Company | Total assets | Turnover |
|---|---|---|
| AgomAb Therapeutics Antwerpen | €251.3m | - |
| Wimble Services Belgium Mechelen | €46.9m | €32.1m |
| TS Holding Balen | €53.5m | €10.7m |
| IDEXX LABORATORIES Brussel | €51.1m | €19.6m |
| Ardena Gent Gent | €58.8m | €26.7m |
| HENOGEN Charleroi | €97.2m | €48.7m |
| Federaal Agentschap voor Nucleaire Controle Brussel | €59.8m | €34.4m |
Key facts about AgomAb Therapeutics
- What is the company number of AgomAb Therapeutics?
- The company number of AgomAb Therapeutics is 0674.527.310. The VAT number is the same number with BE in front: BE 0674.527.310.
- Where is AgomAb Therapeutics based?
- The registered office is at Posthoflei 1, 2600 Antwerpen.Company details
- What does AgomAb Therapeutics do?
- According to the KBO register, the main activity is other technical testing and analysis (NACE 71209).
- What is the legal form of AgomAb Therapeutics?
- The legal form of AgomAb Therapeutics is Public limited company (NV).
- When was AgomAb Therapeutics founded?
- AgomAb Therapeutics was founded on 13-04-2017.
- Is AgomAb Therapeutics still active?
- Yes, AgomAb Therapeutics is an active enterprise in the KBO register.
- How many employees does AgomAb Therapeutics have?
- AgomAb Therapeutics had an average of 52 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does AgomAb Therapeutics fall under?
- In its 2022 annual accounts, AgomAb Therapeutics states joint committee 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of AgomAb Therapeutics?
- The annual accounts for financial year 2025 state no turnover.
- Is AgomAb Therapeutics profitable?
- In financial year 2025, AgomAb Therapeutics made a loss of €9.6m.
- Where can I find the annual accounts of AgomAb Therapeutics?
- AgomAb Therapeutics filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AgomAb Therapeutics due?
- AgomAb Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.